Serum periostin: A novel biomarker for asthma management

Allergology International

Volumn 63, Issue 2, 2014, Pages 153-160

  Matsumoto, Hisako ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Asthma; Companion diagnostic; Pulmonary function decline; Refractory eosinophilia; Serum periostin

Indexed keywords

ANTIASTHMATIC AGENT; CORTICOSTEROID; EOSINOPHIL CATIONIC PROTEIN; FLUTICASONE PROPIONATE; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; LEBRIKIZUMAB; NITRIC OXIDE; OMALIZUMAB; PREDNISOLONE; TRANSCRIPTION FACTOR RUNX2; BIOLOGICAL MARKER; CELL ADHESION MOLECULE; POSTN PROTEIN, HUMAN;

AIRWAY REMODELING; ASTHMA; CALCIUM CELL LEVEL; CALCIUM HOMEOSTASIS; EOSINOPHIL COUNT; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; IN VITRO STUDY; LUNG FUNCTION; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; REVIEW; SMOOTH MUSCLE FIBER; TH2 CELL; BLOOD; DISEASE MANAGEMENT; EOSINOPHIL; IMMUNOLOGY; INFLAMMATION; METABOLISM; PATHOLOGY;

AIRWAY REMODELING; ANTI-ASTHMATIC AGENTS; ASTHMA; BIOLOGICAL MARKERS; CELL ADHESION MOLECULES; DISEASE MANAGEMENT; EOSINOPHILS; HUMANS; INFLAMMATION; TH2 CELLS;

EID: 84901986444     PISSN: 13238930     EISSN: 14401592     Source Type: Journal    
DOI: 10.2332/allergolint.13-RAI-0678     Document Type: Review

References (58)

1. Woodruff PG, Modrek B, Choy DF et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med 2009;180:388-95.
2. Li X, Hawkins GA, Ampleford EJ et al. Genome-wide association study identifies th1 pathway genes associated with lung function in asthmatic patients. J Allergy Clin Immunol 2013;132:313-20. e15.
3. Oboki K, Ohno T, Saito H, Nakae S. Th17 and allergy. Allergol Int 2008;57:121-34.
4. Halwani R, Al-Muhsen S, Hamid Q. T helper 17 cells in airway diseases: From laboratory bench to bedside. Chest 2013;143:494-501.
5. McGrath KW, Icitovic N, Boushey HA et al. A large subgroup of mild-to-moderate asthma is persistently noneosinophilic. Am J Respir Crit Care Med 2012;185:612-9.
6. Wenzel SE. Asthma phenotypes: The evolution from clinical to molecular approaches. Nat Med 2013;18:716-25.
7. Niimi A, Matsumoto H, Amitani R et al. Airway wall thickness in asthma assessed by computed tomography. Relation to clinical indices. Am J Respir Crit Care Med 2000; 162:1518-23.
8. Niimi A, Matsumoto H, Amitani R et al. Effect of shortterm treatment with inhaled corticosteroid on airway wall thickening in asthma. Am J Med 2004;116:725-31.
9. Fahy JV, Liu J, Wong H, Boushey HA. Cellular and biochemical analysis of induced sputum from asthmatic and from healthy subjects. Am Rev Respir Dis 1993;147:1126-31.
10. Rosi E, Scano G. Association of sputum parameters with clinical and functional measurements in asthma. Thorax 2000;55:235-8.
11. Matsumoto H, Niimi A, Takemura M et al. Relationship of airway wall thickening to an imbalance between matrix metalloproteinase-9 and its inhibitor in asthma. Thorax 2005;60:277-81.
12. Baines KJ, Simpson JL, Wood LG, Scott RJ, Gibson PG. Transcriptional phenotypes of asthma defined by gene expression profiling of induced sputum samples. J Allergy Clin Immunol 2011;127:153-60, 60. e1-9.
13. Yamaguchi M, Niimi A, Matsumoto H et al. Sputum levels of transforming growth factor-beta1 in asthma: Relation to clinical and computed tomography findings. J Investig Allergol Clin Immunol 2008;18:202-6.
14. Otsuka K, Matsumoto H, Niimi A et al. Sputum YKL-40 levels and pathophysiology of asthma and chronic obstructive pulmonary disease. Respiration 2012;83:507-19.
15. Nagasaki T, Matsumoto H, Nakaji H et al. Smoking attenuates the age-related decrease in IgE levels and main tains eosinophilic inflammation. Clin Exp Allergy 2013;43: 608-15.
16. Tajiri T, Matsumoto H, Niimi A et al. Association of eosinophilic inflammation with FKBP51 expression in sputum cells in asthma. PLoS One 2013;8:e65284.
17. Matsunaga K, Hirano T, Akamatsu K et al. Exhaled nitric oxide cutoff values for asthma diagnosis according to rhinitis and smoking status in Japanese subjects. Allergol Int 2011;60:331-7.
18. Matsumoto H, Niimi A, Jinnai M et al. Association of alveolar nitric oxide levels with pulmonary function and its reversibility in stable asthma. Respiration 2011;81:311-7.
19. Szefler SJ, Wenzel S, Brown R et al. Asthma outcomes: Biomarkers. J Allergy Clin Immunol 2013;129:S9-23.
20. Wills-Karp M, Luyimbazi J, Xu X et al. Interleukin-13: Central mediator of allergic asthma. Science 1998;282: 2258-61.
21. Barnes PJ. New drugs for asthma. Nat Rev Drug Discov 2004;3:831-44.
22. Arima K, Izuhara K. IL-13/IL-13 receptor interaction, an emerging therapeutic target in allergic disease. Allergol Int 2005;54:229-33.
23. Moro K, Yamada T, Tanabe M et al. Innate production of T(H)2 cytokines by adipose tissue-associated c-Kit(+)Sca-1(+) lymphoid cells. Nature 2013;463:540-4.
24. Matsumoto H, Hirata Y, Otsuka K et al. Interleukin-13 enhanced Ca2+ oscillations in airway smooth muscle cells. Cytokine 2012;57:19-24.
25. Matsumoto H. Effects of inflammatory cytokines on Ca2+ homeostasis in ariway smooth muscle cells. In: Wang YX (ed). Calcium Signaling in Airway Smooth Muscle Cells. Springer, 2013.
26. Park SW, Jangm HK, An MH et al. Interleukin-13 and interleukin-5 in induced sputum of eosinophilic bronchitis: Comparison with asthma. Chest 2005;128:1921-7.
27. Karaman O, Arli O, Uzuner N et al. The effectiveness of asthma therapy alternatives and evaluating the effectivity of asthma therapy by interleukin-13 and interferon gamma levels in children. Allergy Asthma Proc 2007;28: 204-9.
28. Saha SK, Berry MA, Parker D et al. Increased sputum and bronchial biopsy IL-13 expression in severe asthma. J Allergy Clin Immunol 2008;121:685-91.
29. ten Brinke A, Zwinderman AH, Sterk PJ, Rabe KF, Bel EH. Factors associated with persistent airflow limitation in severe asthma. Am J Respir Crit Care Med 2001;164: 744-8.
30. Contoli M, Baraldo S, Marku B et al. Fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease: 5-year follow-up. J Allergy Clin Immunol 2010; 125:830-7.
31. van Veen IH, Ten Brinke A, Sterk PJ et al. Exhaled nitric oxide predicts lung function decline in difficult-to-treat asthma. Eur Respir J 2008;32:344-9.
32. Meijer RJ, Postma DS, Kauffman HF, Arends LR, Koeter GH, Kerstjens HA. Accuracy of eosinophils and eosinophil cationic protein to predict steroid improvement in asthma. Clin Exp Allergy 2002;32:1096-103.
33. Jang AS, Lee JH, Park SW et al. Factors influencing the responsiveness to inhaled glucocorticoids of patients with moderate-to-severe asthma. Chest 2005;128:1140-5.
34. Takayama G, Arima K, Kanaji T et al. Periostin: A novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals. J Allergy Clin Immunol 2006;118:98-104.
35. Woodruff PG, Boushey HA, Dolganov GM et al. Genomewide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids. Proc Natl Acad Sci U S A 2007;104:15858-63.
36. Sidhu SS, Yuan S, Innes AL et al. Roles of epithelial cellderived periostin in TGF-beta activation, collagen production, and collagen gel elasticity in asthma. Proc Natl Acad Sci U S A 2010;107:14170-5.
37. Peters MC, Mekonnen ZK, Yuan S, Bhakta NR, Woodruff PG, Fahy JV. Measures of gene expression in sputum cells can identify Th2-high and Th2-low subtypes of asthma. J Allergy Clin Immunol 2014;133:388-94.
38. Lopez-Guisa JM, Powers C, File D, Cochrane E, Jimenez N, Debley JS. Airway epithelial cells from asthmatic children differentially express proremodeling factors. J Allergy Clin Immunol 2012;129:990-7. e6.
39. Jia G, Erickson RW, Choy DF et al. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. J Allergy Clin Immunol 2012;130:647-54. e10.
40. Kanemitsu Y, Matsumoto H, Izuhara K et al. Increased periostin associates with greater airflow limitation in patients receiving inhaled corticosteroids. J Allergy Clin Immunol 2013;132:305-12. e3.
41. Okamoto M, Hoshino T, Kitasato Y et al. Periostin, a matrix protein, is a novel biomarker for idiopathic interstitial pneumonias. Eur Respir J 2011;37:1119-27.
42. Haldar P, Pavord ID, Shaw DE et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008;178:218-24.
43. Moore WC, Meyers DA, Wenzel SE et al. Identification of asthma phenotypes using cluster analysis in the severe asthma research program. Am J Respir Crit Care Med 2010;181:315-23.
44. Siroux V, Basagana X, Boudier A et al. Identifying adult asthma phenotypes using a clustering approach. Eur Respir J 2011;38:310-7.
45. Amelink M, de Nijs SB, de Groot JC et al. Three phenotypes of adult-onset asthma. Allergy 2013;68:674-80.
46. Nagasaki T, Matsumoto H, Kanemitsu Y et al. Integrating longitudinal information on pulmonary function and inflammation using asthma phenotypes. J Allergy Clin Immunol 2014. DOI: 10.1016/j.jaci 2013.12.1084.
47. Kato G, Takahashi K, Izuhara K, Komiya K, Kimura S, Hayashi S. Markers that can reflect asthmatic activity before and after reduction of inhaled corticosteroids: A pilot study. Biomark Insights 2013;8:97-105.
48. Wenzel S, Ford L, Pearlman D et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 2013;368:2455-66.
49. Corren J, Lemanske RF, Hanania NA et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011;365: 1088-98.
50. Pavord ID, Korn S, Howarth P et al. Mepolizumab for severe eosinophilic asthma (dream): A multicentre, doubleblind, placebo-controlled trial. Lancet 2012;380:651-9.
51. Hanania NA, Wenzel S, Rosen K et al. Exploring the effects of omalizumab in allergic asthma: An analysis of biomarkers in the extra study. Am J Respir Crit Care Med 2013;187:804-11.
52. Ishida A, Ohta N, Suzuki Y et al. Expression of pendrin and periostin in allergic rhinitis and chronic rhinosinusitis. Allergol Int 2012;61:589-95.
53. Tajiri T, Matsumoto H, Hiraumi H et al. Efficacy of omalizumab in eosinophilic chronic rhinosinusitis patients with asthma. Ann Allergy Asthma Immunol 2013;110:387-8.
54. Noonan M, Korenblat P, Mosesova S et al. Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids. J Allergy Clin Immunol 2013;132:567-74. e12.
55. Shoda T, Futamura K, Kobayashi F, Saito H, Matsumoto K, Matsuda A. Cell type-dependent effects of corticosteroid on periostin production by primary human tissue cells. Allergy 2013;68:1467-70.
56. James A, Ono J, Kupczyk M, Ohta S, Izuhara K, Dahlen SEK. Controlled oral steroid intervention decreases serum periostin levels in asthmatic patients [abstract]. Am J Respir Crit Care Med 2013;187:A6005.
57. Scheerens HAJ, Choy DF, Mosesova S, Lal P, Matthews JG. Lebrikizumab treatment reduces serum periostin levels in asthma patients with elevated baseline levels of periostin [abstract]. Am J Respir Crit Care Med 2012;185:A 3960.
58. Izuhara Y, Matsumoto H, Kanemitsu Y et al. GLCCI1 variant accelerates pulmonary function decline in patients with asthma receiving inhaled corticosteroids. Allergy 2014;69:668-73.